Study details
Enrolling now
A Pilot Trial to Assess PYLARIFY PET-CT for Detecting Metastasis
M.D. Anderson Cancer Center
NCT IDNCT05394259ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
36
Study length
about 4.3 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing if PYLARIFY (piflufolastat F18) can be used in imaging scans for patients with breast cancer, liver cancer, or pancreatic cancer. The goal is to see how well PYLARIFY detects metastasis compared to the standard method of diagnosis.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Piflufolastat F18
PhasePhase 1
DrugPiflufolastat F18
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Diagnostic Agent (Imaging Contrast Activity)
Body systems
Oncology